Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;14(4):2183-2187.
doi: 10.21037/tcr-2024-2683. Epub 2025 Apr 15.

Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer

Nelson K Y Wong  1 , Ning Kang  1 , Claire Dourieu  1   2 , Yuzhuo Wang  1   2   3
Affiliations
Editorial

Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer

Nelson K Y Wong et al. Transl Cancer Res. .
No abstract available

Keywords: Prostate cancer (PCa); androgen deprivation therapy (ADT); immune checkpoint; immunotherapy; tumor immune microenvironment (TIME).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2683/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Thomas TS, Pachynski RK. Treatment of Advanced Prostate Cancer. Mo Med 2018;115:156-61. - PMC - PubMed
    1. Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. J Clin Oncol 2023;41:4267-78. 10.1200/JCO.23.00433 - DOI - PMC - PubMed
    1. Crea F, Nur Saidy NR, Collins CC, et al. The epigenetic/noncoding origin of tumor dormancy. Trends Mol Med 2015;21:206-11. 10.1016/j.molmed.2015.02.005 - DOI - PubMed
    1. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res 2020;30:660-9. 10.1038/s41422-020-0343-4 - DOI - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22. 10.1056/NEJMoa1001294 - DOI - PubMed